This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

CVS, Express Scripts call drug rebates 'standard business,' move to dismiss US antitrust claims

( April 15, 2025, 22:31 GMT | Official Statement) -- MLex Summary: CVS and Express Scripts told a US federal judge that pharmaceutical rebates result from hard fought competitive negotiations designed to help curb the impact of the increasing prices of prescription drugs set by manufacturers, thereby benefiting the pharmaceutical benefit managers’ health-plan clients by lowering the net cost of prescription drugs clients pay. Express moved to dismiss claims filed by the State of Vermont accusing it of illegally driving up drug prices and foreclosing patient access to treatments by abusing the market power of its pharmacy benefit management operations' consolidated control of pricing, dispensing and reimbursement systems for prescription drugs. See attached file. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections